Figure 6.
G-GFP-LV induces GFP expression in human platelets in vivo. (A) Schematics and schedule of IO-LV therapy in humanized NMSGW mice. A total of 1 × 106 human CD34+ cells were transplanted to 8- to 10-week-old NBSGW mice. Eight weeks after transplant, mice were IO-injected either with PBS (20 μL per animal) or G-GFP-LV (6.3 × 108 ifu per animal). Platelets from G-GFP-LV–injected humanized NBSGW mice were isolated after clodronate liposome treatment 12 weeks after LV infusion. (B) GFP expression was measured in human platelets by flow cytometry. (C) Summary plot of GFP expression in human platelets after treatment with clodronate liposomes (PBS, n = 4; G-GFP-LV, n = 5). The data are presented as means with standard deviation from 2 separate experiments. ∗P < .05.

G-GFP-LV induces GFP expression in human platelets in vivo. (A) Schematics and schedule of IO-LV therapy in humanized NMSGW mice. A total of 1 × 106 human CD34+ cells were transplanted to 8- to 10-week-old NBSGW mice. Eight weeks after transplant, mice were IO-injected either with PBS (20 μL per animal) or G-GFP-LV (6.3 × 108 ifu per animal). Platelets from G-GFP-LV–injected humanized NBSGW mice were isolated after clodronate liposome treatment 12 weeks after LV infusion. (B) GFP expression was measured in human platelets by flow cytometry. (C) Summary plot of GFP expression in human platelets after treatment with clodronate liposomes (PBS, n = 4; G-GFP-LV, n = 5). The data are presented as means with standard deviation from 2 separate experiments. ∗P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal